Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03847428




Registration number
NCT03847428
Ethics application status
Date submitted
18/02/2019
Date registered
20/02/2019
Date last updated
12/04/2024

Titles & IDs
Public title
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Scientific title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Secondary ID [1] 0 0
2018-004105-85
Secondary ID [2] 0 0
D910DC00001
Universal Trial Number (UTN)
Trial acronym
EMERALD-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Durvalumab
Treatment: Drugs - Bevacizumab
Other interventions - Placebo

Experimental: Arm A - Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)

Experimental: Arm B - Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)

Placebo Comparator: Arm C - Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)


Treatment: Drugs: Durvalumab
Durvalumab IV (intravenous)

Treatment: Drugs: Bevacizumab
Bevacizumab IV (intravenous)

Other interventions: Placebo
Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence-free survival (RFS) for Arm A vs Arm C
Timepoint [1] 0 0
Up to 49 months after first patient randomized
Secondary outcome [1] 0 0
Recurrence-free survival (RFS) Arm B vs Arm C
Timepoint [1] 0 0
Up to 49 months after first patient randomized
Secondary outcome [2] 0 0
Overall Survival (OS) for Arm A vs Arm C and Arm B vs Arm C
Timepoint [2] 0 0
No timeframe
Secondary outcome [3] 0 0
Recurrence-free survival at 24 months (RFS24) and 36 months (RFS36) for Arm A vs Arm C and Arm B vs Arm C
Timepoint [3] 0 0
At 24 and at 36 months
Secondary outcome [4] 0 0
Time to recurrence (TTR) for Arm A vs Arm C and Arm B vs Arm C
Timepoint [4] 0 0
Up to 49 months after first patient randomized
Secondary outcome [5] 0 0
Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C
Timepoint [5] 0 0
Up to 49 months after first patient randomized

Eligibility
Key inclusion criteria
- Histologically or cytologically (or radiologically for patients undergoing curative
ablation), newly diagnosed, confirmed HCC and successfully completed curative therapy
(resection or ablation)

- Imaging to confirm disease-free status within 28 days prior to randomization

- ECOG 0-1 at enrolment

- Child-Pugh score of 5 or 6

- Adequate organ and marrow function.
Minimum age
18 Years
Maximum age
150 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC

- Evidence of metastasis, macrovascular invasion or co-existing malignant disease on
baseline imaging

- History of hepatic encephalopathy within 12 months prior to randomization

- Evidence, by Investigator assessment, of varices at risk of bleeding on upper
endoscopy or contrast-enhanced cross-sectional imaging

- Patients with Vp1 to Vp4 portal vein thrombosis on baseline imaging are excluded

- Active co-infection with HBV and HDV.

- Receipt of prior systemic anticancer therapy for HCC

- Those on a waiting list for liver transplantation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/04/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/05/2027
Actual
Sample size
Target
Accrual to date
Final
908
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Kogarah
Recruitment hospital [2] 0 0
Research Site - Melbourne
Recruitment hospital [3] 0 0
Research Site - Nedlands
Recruitment hospital [4] 0 0
Research Site - Westmead
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Hawaii
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Austria
State/province [24] 0 0
Innsbruck
Country [25] 0 0
Austria
State/province [25] 0 0
Linz
Country [26] 0 0
Austria
State/province [26] 0 0
St. Pölten
Country [27] 0 0
Brazil
State/province [27] 0 0
Florianópolis
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Rio de Janeiro
Country [30] 0 0
Brazil
State/province [30] 0 0
Santa Maria
Country [31] 0 0
Brazil
State/province [31] 0 0
Santo Andre
Country [32] 0 0
Brazil
State/province [32] 0 0
São José do Rio Preto
Country [33] 0 0
Brazil
State/province [33] 0 0
Vitória
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
China
State/province [36] 0 0
Beijing
Country [37] 0 0
China
State/province [37] 0 0
Bengbu
Country [38] 0 0
China
State/province [38] 0 0
Changchun
Country [39] 0 0
China
State/province [39] 0 0
Changsha
Country [40] 0 0
China
State/province [40] 0 0
Chengdu
Country [41] 0 0
China
State/province [41] 0 0
Fuzhou
Country [42] 0 0
China
State/province [42] 0 0
Guangzhou
Country [43] 0 0
China
State/province [43] 0 0
Hangzhou
Country [44] 0 0
China
State/province [44] 0 0
Harbin
Country [45] 0 0
China
State/province [45] 0 0
Hefei
Country [46] 0 0
China
State/province [46] 0 0
Hohhot
Country [47] 0 0
China
State/province [47] 0 0
Nanjing
Country [48] 0 0
China
State/province [48] 0 0
Ningbo
Country [49] 0 0
China
State/province [49] 0 0
Shanghai
Country [50] 0 0
China
State/province [50] 0 0
Tianjin
Country [51] 0 0
China
State/province [51] 0 0
Urumqi
Country [52] 0 0
China
State/province [52] 0 0
Wuhan
Country [53] 0 0
China
State/province [53] 0 0
Xi'an
Country [54] 0 0
China
State/province [54] 0 0
Zhengzhou
Country [55] 0 0
Egypt
State/province [55] 0 0
Alexandria
Country [56] 0 0
Egypt
State/province [56] 0 0
Assiut
Country [57] 0 0
Egypt
State/province [57] 0 0
Cairo
Country [58] 0 0
Egypt
State/province [58] 0 0
Dakahlia
Country [59] 0 0
Egypt
State/province [59] 0 0
New Cairo
Country [60] 0 0
Egypt
State/province [60] 0 0
Shebeen El Kom
Country [61] 0 0
France
State/province [61] 0 0
Amiens Cedex 1
Country [62] 0 0
France
State/province [62] 0 0
ANGERS Cedex 9
Country [63] 0 0
France
State/province [63] 0 0
Besançon
Country [64] 0 0
France
State/province [64] 0 0
Clichy
Country [65] 0 0
France
State/province [65] 0 0
Dijon Cedex
Country [66] 0 0
France
State/province [66] 0 0
Nantes
Country [67] 0 0
France
State/province [67] 0 0
Nice
Country [68] 0 0
France
State/province [68] 0 0
PARIS Cedex 12
Country [69] 0 0
France
State/province [69] 0 0
Pessac
Country [70] 0 0
France
State/province [70] 0 0
Toulouse Cedex 9
Country [71] 0 0
France
State/province [71] 0 0
TOURS Cedex 9
Country [72] 0 0
Germany
State/province [72] 0 0
Berlin
Country [73] 0 0
Germany
State/province [73] 0 0
Bonn
Country [74] 0 0
Germany
State/province [74] 0 0
Chemnitz
Country [75] 0 0
Germany
State/province [75] 0 0
Freiburg
Country [76] 0 0
Germany
State/province [76] 0 0
Heidelberg
Country [77] 0 0
Germany
State/province [77] 0 0
Köln
Country [78] 0 0
Germany
State/province [78] 0 0
Leipzig
Country [79] 0 0
Germany
State/province [79] 0 0
Lübeck
Country [80] 0 0
Germany
State/province [80] 0 0
München
Country [81] 0 0
Germany
State/province [81] 0 0
Tuebingen
Country [82] 0 0
Hong Kong
State/province [82] 0 0
Hong Kong
Country [83] 0 0
Hong Kong
State/province [83] 0 0
HongKong
Country [84] 0 0
Hong Kong
State/province [84] 0 0
Kwai Chung
Country [85] 0 0
Hong Kong
State/province [85] 0 0
Shatin
Country [86] 0 0
India
State/province [86] 0 0
Bangalore
Country [87] 0 0
India
State/province [87] 0 0
Hyderabad
Country [88] 0 0
India
State/province [88] 0 0
Kolkata
Country [89] 0 0
India
State/province [89] 0 0
Mumbai
Country [90] 0 0
India
State/province [90] 0 0
New Delhi
Country [91] 0 0
Italy
State/province [91] 0 0
Bologna
Country [92] 0 0
Italy
State/province [92] 0 0
Milano
Country [93] 0 0
Italy
State/province [93] 0 0
Napoli
Country [94] 0 0
Italy
State/province [94] 0 0
Roma
Country [95] 0 0
Italy
State/province [95] 0 0
Tricase, Lecce
Country [96] 0 0
Italy
State/province [96] 0 0
Verona
Country [97] 0 0
Japan
State/province [97] 0 0
Bunkyo-ku
Country [98] 0 0
Japan
State/province [98] 0 0
Fukuoka-shi
Country [99] 0 0
Japan
State/province [99] 0 0
Gifu-shi
Country [100] 0 0
Japan
State/province [100] 0 0
Hiroshima-shi
Country [101] 0 0
Japan
State/province [101] 0 0
Koto-ku
Country [102] 0 0
Japan
State/province [102] 0 0
Kumamoto-shi
Country [103] 0 0
Japan
State/province [103] 0 0
Kurume-shi
Country [104] 0 0
Japan
State/province [104] 0 0
Kyoto-shi
Country [105] 0 0
Japan
State/province [105] 0 0
Matsuyama-shi
Country [106] 0 0
Japan
State/province [106] 0 0
Mitaka-shi
Country [107] 0 0
Japan
State/province [107] 0 0
Musashino-shi
Country [108] 0 0
Japan
State/province [108] 0 0
Nagasaki-shi
Country [109] 0 0
Japan
State/province [109] 0 0
Nagoya-shi
Country [110] 0 0
Japan
State/province [110] 0 0
Osaka-shi
Country [111] 0 0
Japan
State/province [111] 0 0
Osakasayama-shi
Country [112] 0 0
Japan
State/province [112] 0 0
Sapporo-shi
Country [113] 0 0
Japan
State/province [113] 0 0
Sendai-shi
Country [114] 0 0
Japan
State/province [114] 0 0
Shinagawa-ku
Country [115] 0 0
Japan
State/province [115] 0 0
Shinjuku-ku
Country [116] 0 0
Japan
State/province [116] 0 0
Shiwa-gun
Country [117] 0 0
Japan
State/province [117] 0 0
Takasaki-shi
Country [118] 0 0
Japan
State/province [118] 0 0
Tsu-shi
Country [119] 0 0
Japan
State/province [119] 0 0
Wakayama-shi
Country [120] 0 0
Japan
State/province [120] 0 0
Yokohama-shi
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Busan
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Daegu
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Seoul
Country [124] 0 0
Peru
State/province [124] 0 0
Lima
Country [125] 0 0
Peru
State/province [125] 0 0
San Isidro
Country [126] 0 0
Philippines
State/province [126] 0 0
Manila
Country [127] 0 0
Philippines
State/province [127] 0 0
Muntinlupa City
Country [128] 0 0
Philippines
State/province [128] 0 0
Pasig City
Country [129] 0 0
Poland
State/province [129] 0 0
Bydgoszcz
Country [130] 0 0
Poland
State/province [130] 0 0
Gdansk
Country [131] 0 0
Poland
State/province [131] 0 0
Poznan
Country [132] 0 0
Poland
State/province [132] 0 0
Warszawa
Country [133] 0 0
Puerto Rico
State/province [133] 0 0
Ponce
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Barnaul
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Ekaterinburg
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Moscow
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Obninsk
Country [138] 0 0
Russian Federation
State/province [138] 0 0
Saint Petersburg
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Saint-Petersburg
Country [140] 0 0
Singapore
State/province [140] 0 0
Singapore
Country [141] 0 0
Taiwan
State/province [141] 0 0
Changhua
Country [142] 0 0
Taiwan
State/province [142] 0 0
Tainan
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taipei
Country [144] 0 0
Taiwan
State/province [144] 0 0
Taoyuan City
Country [145] 0 0
Taiwan
State/province [145] 0 0
Yunlin
Country [146] 0 0
Thailand
State/province [146] 0 0
Bangkok
Country [147] 0 0
Thailand
State/province [147] 0 0
Chiang Mai
Country [148] 0 0
Thailand
State/province [148] 0 0
Hat Yai
Country [149] 0 0
Thailand
State/province [149] 0 0
Khon Kaen
Country [150] 0 0
Thailand
State/province [150] 0 0
Pathumthani
Country [151] 0 0
Turkey
State/province [151] 0 0
Ankara
Country [152] 0 0
Turkey
State/province [152] 0 0
Istanbul
Country [153] 0 0
Turkey
State/province [153] 0 0
Izmir
Country [154] 0 0
Turkey
State/province [154] 0 0
Malatya
Country [155] 0 0
Vietnam
State/province [155] 0 0
Hanoi
Country [156] 0 0
Vietnam
State/province [156] 0 0
Ho Chi Minh city
Country [157] 0 0
Vietnam
State/province [157] 0 0
Ho Chi Minh
Country [158] 0 0
Vietnam
State/province [158] 0 0
Hochiminh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A global study to assess the efficacy and safety of durvalumab in combination with
bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high
risk of recurrence.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03847428
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jia Fan, PhD
Address 0 0
Liver Cancer Institute Zhongshan Hospital, Fudan University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03847428